NAS:AFMD (Germany)  
Affimed NV logo

Affimed NV

$ 2.12 +0.03 (+1.44%) 10:08 PM EST
P/E:
At Loss
P/B:
1.77
Market Cap:
$ 316.60M
Enterprise V:
$ 97.17M
Volume:
2.07M
Avg Vol (2M):
1.85M
Also Trade In:
Volume:
2.07M
Market Cap $:
316.60M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.85M
Enterprise Value $:
97.17M
PB Ratio:
1.77
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.
Name Current Vs Industry Vs History
Cash-To-Debt 11.9
Equity-to-Asset 0.77
Debt-to-Equity 0.1
Debt-to-EBITDA -0.24
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.16
Distress
Grey
Safe
Beneish M-Score -3.09
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 54.53
9-Day RSI 52.72
14-Day RSI 52.46
6-1 Month Momentum % -37.1
12-1 Month Momentum % -67.87

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.65
Quick Ratio 5.63
Cash Ratio 5.46
Days Sales Outstanding 38.03

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -25.5

Financials (Next Earnings Date:2023-03-31 Est.)

AFMD's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:AFMD

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 42.957
EPS (TTM) ($) -0.615
Beta 2.21
Volatility % 47.78
14-Day RSI 52.46
14-Day ATR ($) 0.169205
20-Day SMA ($) 2.155
12-1 Month Momentum % -67.87
52-Week Range ($) 1.4 - 6.91
Shares Outstanding (Mil) 149.34

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Affimed NV Filings

Document Form Filing Date
No Filing Data

Affimed NV Analysis

Share your research

Headlines

See More
No news.